Financial and Corporate Situation - AB Science reported an operating deficit of €6.1 million as of December 31, 2024, a decrease of 55% compared to €13.4 million in 2023 [6][26] - The cash position stood at €8.0 million as of December 31, 2024 [6] - Operating income increased by 10% to €1.072 million in 2024 from €0.970 million in 2023 [27] - Operating expenses decreased by 50%, amounting to €7.244 million less than in 2023 [27][28] Clinical Development - AB Science provided updates on the AB8939 microtubule program, which targets relapsed/refractory acute myeloid leukaemia (AML) [3][4] - The Phase 1 study of AB8939 included 28 patients, assessing the maximum tolerated dose after 3 consecutive days of treatment, with a second stage nearing completion for 14 consecutive days [4][5] - AB8939 showed a 50% response rate against the MECOM gene rearrangement, which is associated with poor prognosis in AML [7][8] Masitinib Platform - Positive results were reported from the Phase 2 study of masitinib in COVID-19, with an odds ratio of 2.4 in favor of the treatment arm after 15 days [16][18] - The European Medicines Agency (EMA) issued a negative opinion for the conditional marketing authorization of masitinib in ALS [19] - A new confirmatory study for masitinib in ALS will be launched, targeting the best responders [21] Intellectual Property Developments - AB Science secured intellectual property rights for AB8939 in AML until 2036 and potentially until 2044 for specific chromosomal abnormalities [8] - New patents were granted for masitinib in the treatment of severe systemic mastocytosis, sickle cell disease, and other indications, extending protection until 2041 or 2042 [23][25][24] Capital Increase and Financial Strategy - A capital increase of €5 million was announced through the issuance of 5,368,725 new ordinary shares [31][34] - The proceeds from the capital increase will support AB Science's activities over the next twelve months [36] - The company has engaged in a Term Capital Increase Program (PACT) with Alpha Blue Ocean, which has provided additional funding [37] Market Position and Analyst Coverage - AB Science has received coverage initiation from DNA Finance and In Extenso Finance, with strong buy opinions indicating a compelling investment opportunity in the biotech sector [41][42]

Core Insights - Banco Comercial Português, S.A. has reported the Q1 2025 results for Bank Millennium in Poland, indicating a significant performance in the banking sector [1] Financial Performance - Bank Millennium's net profit for Q1 2025 reached €50 million, reflecting a 15% increase compared to the same period last year [1] - The bank's total assets grew to €20 billion, marking a 10% year-over-year increase [1] - The return on equity (ROE) improved to 12%, up from 10% in Q1 2024 [1] Operational Highlights - The bank's loan portfolio expanded by 8% year-over-year, reaching €15 billion [1] - Customer deposits increased by 12%, totaling €18 billion [1] - The cost-to-income ratio improved to 45%, down from 50% in the previous year [1] Market Position - Bank Millennium continues to strengthen its market position in Poland, benefiting from a growing economy and increased consumer confidence [1] - The bank's digital banking services have seen a 20% increase in active users, reflecting a shift towards online banking solutions [1]

Group 1 - VILVI Group reported consolidated sales of EUR 23.20 million for April 2025, representing a 26.2% increase compared to April 2024 [1] - For the period from January to April 2025, the Group's consolidated sales reached EUR 94.26 million, marking a 26.5% increase compared to the same period last year [1]

Core Insights - The phase 3 REAL8 study demonstrated that once-weekly Sogroya (somapacitan) is non-inferior to once-daily Norditropin (somatropin) in improving yearly growth rate in pre-pubertal children with growth disorders [1][6][9] - Sogroya showed superiority in height velocity for children with Noonan syndrome and compared favorably against lower doses of daily growth hormone in children born small for gestational age [1][7][8] Group 1: Study Results - Sogroya was well-tolerated with no safety issues compared to daily growth hormone, and IGF-1 response was similar between the two treatments [2][6] - The trial achieved primary endpoints across three sub-studies, confirming the efficacy of once-weekly Sogroya [3][6] - In children born SGA, Sogroya had a mean height velocity of 11.0 cm/year compared to 9.4 cm/year for a lower dose of somatropin, and was non-inferior to a higher dose [7][8] Group 2: Treatment Adherence - Non-adherence to daily growth hormone treatment is a significant issue, with missed doses leading to substantial height differences over time [4][5] - The once-weekly administration of Sogroya aims to reduce treatment burden and improve adherence, potentially enhancing health outcomes for children [5][6] Group 3: Regulatory and Developmental Aspects - The indications for Sogroya (SGA, Noonan syndrome, and idiopathic short stature) have been submitted for regulatory review in the EU and US based on REAL8 and REAL9 data [8][9] - REAL8 employs an innovative basket trial design, allowing for efficient clinical development across multiple related indications [10][11]

Core Insights - Aspo Plc reported a strong start to 2025 with continued profitability improvement, achieving net sales of EUR 151.2 million, a 13.9% increase compared to the same period in 2024 [7][11][19] - The company expects comparable EBITA for 2025 to be between EUR 35 million and EUR 45 million, up from EUR 29.1 million in 2024 [3][4] Financial Performance - Net sales increased to EUR 151.2 million from EUR 132.7 million in Q1 2024 [9] - Comparable EBITA grew to EUR 8.8 million, representing 5.8% of net sales, compared to EUR 5.1 million and 3.8% in the previous year [9][12] - The profit for the period was EUR 3.9 million, a recovery from a loss of EUR 6.0 million in Q1 2024 [9] - Comparable earnings per share rose to EUR 0.13 from EUR 0.09 [9] Business Segments - ESL Shipping's comparable EBITA improved to EUR 4.1 million from EUR 2.7 million, despite weak demand and low pricing in the spot market [9][13] - Telko's comparable EBITA increased to EUR 4.4 million from EUR 2.3 million, driven by acquisitions and organic growth [9][14] - Leipurin's comparable EBITA was EUR 1.5 million, up from EUR 1.2 million, benefiting from supply chain efficiency improvements [9][14] Strategic Outlook - The company anticipates a challenging operating environment in the first half of 2025, with gradual improvement expected in the second half, supported by increased defense and infrastructure spending in Europe [4] - Aspo aims to achieve a financial ambition of EUR 1 billion in net sales and an EBITA margin of 8% by 2028, with a total investment program of EUR 300–350 million planned for 2024–2028 [17][18] - The company is focused on integrating acquisitions and enhancing organic growth while managing profitability improvement actions across all business units [10][18]

Core Viewpoint - Elis has disclosed the purchase of its own shares from May 5 to May 9, 2025, as part of its share buyback program authorized by the General Shareholders' Meeting [2]. Summary by Relevant Sections Share Buyback Details - The share buyback program was authorized by the 19th resolution of the General Shareholders' Meeting on May 23, 2024, and announced on March 6, 2025 [2]. - A total of 168,032 shares were acquired during the specified period, with an average purchase price of €22.6431 per share [2]. Daily Transactions - On May 5, 2025, 30,383 shares were purchased at €23.1099 [2]. - On May 6, 2025, a total of 55,165 shares were acquired (38,008 at €22.5315 and 17,157 at €22.3692) [2]. - On May 7, 2025, 56,000 shares were bought (32,000 at €22.5209 and 24,000 at €22.4811) [2]. - On May 8, 2025, 1,570 shares were purchased at €22.5408 [2]. - On May 9, 2025, 24,914 shares were acquired at €22.7522 [2]. Purpose of Share Purchases - The purpose of the share buyback is to cover maturing performance share plans and allocate free shares to employees as part of the Elis for All 2025 international employee shareholding plan [2]. - Additionally, the shares are intended to be canceled in accordance with the 30th resolution of the Combined General Meeting on May 23, 2024 [2].

Core Points - The annual general meeting of Arco Vara AS is scheduled for June 5, 2025, at 5:15 PM in Tallinn [1] - The agenda includes the approval of the annual report for 2024, distribution of profit and dividend payment, and approval of management remuneration principles [2][3] - The proposed dividend is EUR 0.02 per share, with a payment date set for November 12, 2025 [4] - The meeting will also address the extension of the Supervisory Board's authorizations and the approval of their remuneration [5][6] - An amendment to the Articles of Association is proposed to adjust the minimum and maximum share capital [7] - A directed share issue is planned to raise capital for the acquisition and development of the Luther Quarter, involving new investors [7][8] - The share capital increase will involve issuing 6,980,000 new ordinary shares at an issue price of EUR 2.5 per share [8] - Shareholders can submit questions and proposals regarding the agenda items via email, with specific deadlines for submissions [10][11] Financial Details - The company plans to cover a net loss of EUR 624 thousand from retained earnings [4] - The new share capital after the proposed increase will be EUR 12,157,856.90 [8] - Alarmo Kapital OÜ will subscribe to 2,100,000 shares, contributing EUR 5,250,000 [8] - Luther Factory OÜ and Luther Factory Holding OÜ will also subscribe to significant portions of the new shares, contributing EUR 8,274,997.50 and EUR 3,925,002.50 respectively [8]

Acquisition Overview - Arco Vara AS subsidiaries have acquired full ownership of the Luther Quarter, consisting of 15 properties in central Tallinn, with a gross building volume of 95,000 m², including 18,500 m² of commercial space and 33,000 m² of net residential area [1] - The acquisition price for the Luther Quarter is €35 million, with a total estimated investment for the project amounting to €205 million [2] Development Plans - Over the next eight years, Arco Vara plans to develop the former industrial area into a modern mixed-use urban quarter, including commercial space, residential properties, and public areas, with construction scheduled to begin in 2026 [3] - The presale of the first phase, which includes the development of four buildings, is also planned for 2026 [3] Financing Structure - The purchase price will be paid to the sellers in Arco Vara AS shares, cash, and through the modified assumption of loan obligations with AS LHV Pank [4] - An additional €17.5 million in investment is required for the development, leading to a directed share issue aimed at Alarmo Kapital OÜ and the previous owners of the Luther Quarter properties [5] Share Capital Increase - The directed share issue will involve issuing 6,980,000 new shares at an issue price of €2.50 per share, with €0.70 as nominal value and €1.80 as share premium [6] - The share price was agreed upon considering the financial interests of existing and new shareholders, the average market price before the deal, and the potential synergies created by the transaction [7] Loan Agreement - Arco Vara AS has entered into a loan agreement with majority shareholder Alarmo Kapital OÜ at an annual interest rate of 6%, providing a loan of €12 million [8] - Alarmo Kapital OÜ will also subscribe to 2,100,000 shares for a total of €5.25 million, resulting in Alarmo Kapital OÜ holding at least 8,780,000 shares post-transaction [8] Strategic Insights - The transaction is expected to double Arco Vara's asset volume while maintaining the equity-to-debt ratio, with a projected tripling of development potential due to existing building permits exceeding 70,000 square meters [9] - The management expresses confidence in Tallinn's growth and the capabilities of Arco Vara's team [9]

Group 1 - Stolt-Nielsen Limited (SNI) has completed its share buy-back program initiated in 2016, with a total repurchase amounting to NOK 92,241,003 for 403,000 shares [1][4] - The recent share purchases from May 5 to May 8, 2025, totaled 103,000 shares at an average price of NOK 239.5063 per share, adhering to "safe harbor" rules [2][3] - Following the completion of the buy-back program, SNI now holds a total of 5,403,000 own shares, representing 9.232% of its share capital [4] Group 2 - The buy-back program had a remaining budget of $8,754,827.55 at the time of its continuation announcement on April 3, 2025 [1] - The average price per share for the total repurchases under the program was NOK 228.8859 [4] - Stolt-Nielsen Limited is engaged in logistics, distribution, and aquaculture, with a portfolio that includes global bulk-liquid and chemicals logistics businesses [6][7]

The shares in Norsk Hydro ASA will be traded ex-dividend of NOK 2.25 as from today, May 12, 2025. Investor contact: Elitsa Blessi +47 91775472 Elitsa.Blessi@hydro.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...